U.S. NUCLEAR REGULATORY COMMISSION

Amendment No. 49

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	In accordance with letter dated February 23, 2024,	4. Expiration Date: March 31, 2025
1. Norton Clark Hospital, LLC d/b/a Norton Clark Hospital		
2. 1220 Missouri Ave. Jeffersonville, IN 47130	3. License No.: 13-12367-01 is amended in its entirety to read as follows:	5. Docket No.: 030-01658 Reference No.:

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license	9. Authorized use
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As Needed	A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As Needed	B. For use in imaging and localization studies permitted by 10 CFR 35.200.
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. 1 curie total	C. For any use permitted by 10 CFR 35.300.
D. Any byproduct material permitted by 10 CFR 31.11	D. Prepackaged Kits	D. 2 millicuries total	D. For use in in-vitro studies.
E. Strontium-90	E. Sealed Sources	E. 100 millicuries total	E. For possession only, incident to disposal.

MATERIALS LICENSE SUPPLEMENTARY SHEET	License No.: 13-12367-01	Docket or Reference No.: 030-01658
	Amendment No. 49	

CONDITIONS

10. Licensed material may be used or stored at the licensee's facilities located at 1220 Missouri Ave., Jeffersonville, Indiana, 47130.

11. The Radiation Safety Officer (RSO) for this license is Jodi Daves.

12. Licensed material shall only be used by, or under the supervision of:

A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.

B. The following individuals are authorized users for the material and medical uses as indicated:

Authorized User (M.D.,D.O.,etc.)	Material and Use
Arpit Agrawal, M.D.	10 CFR 35.100,10 CFR 35.200
Jason N. Bronfman, M.D.	10 CFR 35.100,10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)
Christopher B. Cornell, M.D.	10 CFR 35.100,10 CFR 35.200
Bryan M. Denham, M.D.	10 CFR 35.100,10 CFR 35.200
Ibrahim Fahsah, M.D.	10 CFR 35.100,10 CFR 35.200
Satya Garimella, M.D.	10 CFR 35.200
Lawrence Hochman, D.O.	10 CFR 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries, and the parenteral administration of unsealed byproduct material requiring a written directive)
Christopher S. Hofelich, M.D	10 CFR 35.200
Michael Hogan, M.D.	10 CFR 35.100,10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)

MATERIALS LICENSE SUPPLEMENTARY SHEET	License No.: 13-12367-01	Docket or Reference No.: 030-01658
	Amendment No. 49	

Authorized User (M.D.,D.O.,etc.)	Material and Use
Robert L. Hooker, M.D.	10 CFR 35.100,10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries)
Robert J. Kadner, M.D.	10 CFR 35.100,10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)
John Terrence Kenny, M.D.	10 CFR 35.100,10 CFR 35.200
Kamal J. Khiani, M.D.	10 CFR 35.100,10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries)
Katrina Lambert, M.D.	10 CFR 35.100,10 CFR 35.200
Andrew L. Laurel, M.D.	10 CFR 35.100,10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)
Frank E. Lee, M.D.	10 CFR 35.100,10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)
Maurice D. Linkous, M.D.	10 CFR 35.100,10 CFR 35.200
Christopher M. Massey, M.D.	10 CFR 35.100,10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries)
David Musich, M.D.	10 CFR 31.11,10 CFR 35.300
Jacob Nunamaker, M.D.	10 CFR 35.100,10 CFR 35.200
Zaka Ur Rahman, M.D.	10 CFR 35.100,10 CFR 35.200
Syed Raza, M.D.	10 CFR 35.200
Daren D. Repishti, M.D.	10 CFR 35.100,10 CFR 35.200
Ali Nawab Risvi, M.D.	10 CFR 35.100,10 CFR 35.200
Brent A. Roach, M.D.	10 CFR 35.100,10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)
Armand Rothschild, M.D.	10 CFR 35.100,10 CFR 35.200
Gregory Sanders, M.D.	10 CFR 35.100,10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)
William J. Schoen, M.D.	10 CFR 35.100,10 CFR 35.200
Anil K. Sharma, M.D.	10 CFR 35.200

MATERIALS LICENSE SUPPLEMENTARY SHEET	License No.: 13-12367-01	Docket or Reference No.: 030-01658
	Amendment No. 49	

Authorized User (M.D.,D.O.,etc.)	Material and Use
Wayne Shugoll, M.D.	10 CFR 35.100,10 CFR 35.200
Naresh Solankhi, M.D.	10 CFR 35.100,10 CFR 35.200
Shannon Steed, M.D.	10 CFR 35.100,10 CFR 35.200
Mio Michael Stikovac, M.D	10 CFR 35.200
John E. Sunderland, M.D.	10 CFR 35.100,10 CFR 35.200
Thomas Matthew Sweat, M.D.	10 CFR 35.100,10 CFR 35.200

13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Application dated September 19, 2014 (ML14268A305)
B. Letter dated February 25, 2015 (ML15062A543)
C. Letter dated August 12, 2015 (ML15225A556)
D. Letter dated August 10, 2016 (ML16229A421)
E. Letter dated June 8, 2017 (ML17163A160)
F. Letter dated August 28, 2018 (ML18241A252)
G. Letter dated September 20, 2018 (ML18290A542)
H. Letter dated November 16, 2018 (ML18323A465)
I. Letter dated June 13, 2019 (ML19178A066)

MATERIALS LICENSE SUPPLEMENTARY SHEET	License No.: 13-12367-01	Docket or Reference No.: 030-01658
	Amendment No. 49	

J. Letter dated August 23, 2022 (ML22238A061)
K. Letter dated June 1, 2023 (ML23156A159)
L. Letter dated September 20, 2023 (ML23265A257)
M. Letter dated December 19, 2023 (ML23363A157)

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: April 18, 2024

By: MAGDALENA GRYGLAK Digitally signed by MAGDALENA GRYGLAK Date: 2024.04.18 13:30:31 -05'00'

Magdalena R. Gryglak
Region 3